C-Diff Treatment Study
Ferring Pharmaceuticals is conducting an observational research study utilizing the medication REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients
REBYOTA has been recently approved by the U.S. Food and Drug Administration (FDA) to prevent recurrence of CDI. This drug has been approved in individuals 18 years of age and older, following completion of antibiotic treatment for recurrent CDI.
The purpose of this study is to better understand how well the medication REBYOTA is working to prevent recurrence of CDI among adults following antibiotic treatment. The study also aims to understand patient-reported outcomes and health care utilization (e.g., doctors’ visits, hospitalizations) after receiving REBYOTA in a real-world setting.
Up to $160
Are you eligible to participate?
Age ≥ 18 years
Diagnosis of rCDI as determined by the treating physician
Completed antibiotic treatment for the presenting rCDI episode
Prescription for REBYOTA to prevent rCDI according to the approved indication